论文部分内容阅读
已知干扰素(IFN)可有效治疗乙型肝炎病毒(HBV)相关的慢性肝炎,但对其远期疗效即对肝细胞 癌(HCC)发生的影响尚不明了。鉴于80％以上HCC与肝硬变相关的事实,如何预防这种肝癌的发生极为重要。现探讨IFN对HBV相关肝硬变病人HCC发生的作用。 对313例确诊为HBV相关肝硬变病人进行了对照研究,其中94例(30.0％)接受间断性IFN治疗,为期6个月或以上。另219例既未用IFN,也未给其它抗病
Interferon (IFN) is known to be effective in the treatment of hepatitis B virus (HBV)-associated chronic hepatitis, but its long-term efficacy, namely the occurrence of hepatocellular carcinoma (HCC), is unknown. Given the fact that more than 80% of HCC is associated with liver cirrhosis, how to prevent this type of liver cancer is extremely important. The role of IFN in the development of HCC in patients with HBV-related cirrhosis is now being investigated. A controlled study of 313 patients with confirmed HBV-related cirrhosis was performed, 94 of whom (30.0%) received intermittent IFN for a period of 6 months or more. Another 219 patients neither used IFN nor given other disease resistance